Lobbying client

ADURO BIOTECH

Develop early stage cancer therapies

The register keeps a separate record of this client for every firm that files for it and every spelling of its name. All 2 of its records are shown together here.

Filings
61
Filed by
2
Reported in-house
—
Reported by firms
$540,000

Reported lobbying by year

The larger of in-house and firm-reported each year, $ thousands 2009 to 2020

Filings

7 filings for 2016, newest first.
Filing Filed by Amount
4th Quarter - Amendment
4th Quarter 2016
U.S. GOVERNMENT RELATIONS INTL. — reported
4th Quarter - Reportreplaced
4th Quarter 2016
U.S. GOVERNMENT RELATIONS INTL. — reported
4th Quarter - Report
4th Quarter 2016
INNOVATIVE FEDERAL STRATEGIES, LLC $20,000 reported
Registration
4th Quarter 2016
U.S. GOVERNMENT RELATIONS INTL. — reported
3rd Quarter - Report
3rd Quarter 2016
INNOVATIVE FEDERAL STRATEGIES, LLC $20,000 reported
2nd Quarter - Report
2nd Quarter 2016
INNOVATIVE FEDERAL STRATEGIES, LLC $20,000 reported
1st Quarter - Report
1st Quarter 2016
INNOVATIVE FEDERAL STRATEGIES, LLC $20,000 reported

Filed by

Each firm that has reported for this client, and the client itself where it lobbies in-house, with the reports filed and the amounts they disclose.

Issues lobbied

How many report sections named each issue, counting the current version of each report.

Bills named in its filings

Bill numbers found in the filers' descriptions, most often named first.

BillCongressTimes named
H.R. 2397 113th 4
H.R. 2685 114th 3
S. 3000 114th 3
S. 1558 114th 3
H.R. 5293 114th 3
S. 1429 113th 3
H.R. 5856 112th 3
H.R. 1540 112th 3
H.R. 4310 112th 3
H.R. 5136 111th 3
H.R. 2647 111th 3
H.R. 4870 113th 2
H.R. 2219 112th 2
S. 1253 112th 2
H.R. 3326 111th 2
H.R. 933 113th 1
H.R. 2055 112th 1
H.R. 1 112th 1

From reports filed under the Lobbying Disclosure Act. Firms report what each client paid them; an organisation lobbying for itself reports its own expenses. Amounts count the current version of each report once.